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Our laboratory has developed a murine model of lymphoma via breast milk transmission of MoMuLV-ts-1 (Moloney murine
leukemia virus-temperature sensitive mutant-1). Uninfected oﬀspring suckled from infected surrogate mothers become infected
and develop lymphoma. Multiple gene integration sites of ts-1 into the infected mouse genome including tacc3, aurka, ndel1, tpx2,
p53, and rhamm were identiﬁed, and mRNA expressions were quantitated. These genes produce centrosomal proteins, which may
beinvolvedinabnormalchromosomalsegregationleadingtoaneuploidyormultiploidy,thuscausinglymphoma.Sincethereisno
report to date on this retroviral model leading to centrosomal abnormality, and causing lymphoma development, this is a valuable
and unique model to study the centrosomal involvement in lymphomagenesis.
1.Introduction
Retroviral infections in humans range from asymptomatic
murine leukemia virus infections to deadly infections such
as HIV. The HIV epidemic has spurred unprecedented levels
ofretroviralresearchinthelastthreedecadesduetotheever-
increasing human toll. According to the WHO and UNAIDS
report in 2008 [1], globally 33.4 million people are now
living with HIV. Of these, 2.1 million children under the age
of 15 years are suﬀering from HIV infection and 280,000
children died of AIDS and AIDS-related conditions such as
lymphoma in 2008. In 2008, an additional 430,000 children
became infected, with the vast majority living in developing
countries with little access to antiretroviral therapy (ART).
The main route of infection in these children is mother to
child transmission (MTCT). Although treatment of infected
mothers during pregnancy with ART and use of infant
formula after delivery has limited MTCT of HIV-1 in
developed countries [1], these options are often unavailable
in Africa and other developing countries where MTCT still
remains a signiﬁcant source of HIV infection.
Due to practical and ethical constraints involving human
subjects, the mechanism of perinatal transmission of HIV-
1 is not yet fully understood. HIV can be transmitted
to the fetus/infant during prenatal and postnatal periods.
A suitable animal model may allow in depth study of
the pathophysiologic mechanisms of MTCT of HIV. We
have successfully developed a murine model for mother-to-
oﬀspring transmission of Moloney Murine Leukemia virus
(MoMuLV) ts-1, a retrovirus which mimics HIV. We have
clearly demonstrated that the transmission of ts-1 can occur
in utero, intrapartum, and/or postpartum. Transmission
of ts-1 produces an immunodeﬁciency state with wasting,
increased infection, and neurologic deterioration. In addi-
tion, postpartum transmission of ts-1 is associated with an
increased development of lymphoma in pups [2, 3].
Chakraborty et al. [4] have found that ts-1 integration
leads to an overexpression of four genes associated with
lymphoma in BALB/c mice infected by breast milk. This
unique model has allowed us to demonstrate ts-1 retrovirus
transmission via breast milk and study the molecular
mechanism of the lymphoma development through natural2 Advances in Virology
Table 1: Comparison between HIV and MoMuLV-ts-1 showing the
similarities and diﬀerences between these two types of viruses.
Characteristics HIV ts-1
Retrovirus + +
Lentivirus + −∗
Initial target for infection: CD4 cells + +
Depletion of T-lymphocytes + +
T-cell death via apoptosis + +
Ineﬃcient transport of env precursor + +
Viral induced cytokine production + +
Polyclonal activation of B lymphocytes + +
Infection of astrocytes and microglia + +
Demyelination + +
Neuronal death + +
Wasting + +
Can cause lymphoma in some cases∗∗∗ ++
Horizontal transmission + −∗∗
Mother-to-oﬀspring transmission + +
Can cause disease New born
and adult
New born
only
∗MoMuLV-ts-1: mammalian gamma oncoretrovirus. ∗∗ts-1: No adult
mouse can be infected; therefore, no sexual transmission occurs. ∗∗∗:B o t h
HIV and ts-1 may indirectly cause lymphoma.
transmission of a retrovirus to the oﬀspring. Our hypothesis
is that viral integration into the host genome alters host gene
expression leading to an abnormal mRNA expression and
abnormal protein production. These abnormal proteins alter
the centrosome function during the cell cycle resulting in
lymphomagenesis. This paper will explore two related areas
of ts-1 research: ts-1 as a small animal model of perinatal
retroviral transmission and ts-1 in lymphomagenesis.
2.PartI.MoMuLV-ts-1asaSmallAnimalModel
2.1. The Similarities and Diﬀerences between HIV and
MoMuLV-ts-1. HIV shares many characteristics with ts-
1. These include CD4 cell targeting, secondary infections,
neurodegenerative diseases, macrophage and CD4 cell infec-
tion, immunodeﬁciency, neurotropism, CD4 cell depletion,
wasting, lymphomas, and perinatal transmission. However,
the mechanism of entry of these two viruses are diﬀerent.
The Moloney murine leukemia virus (MoMuLV) ts-1 is a
temperature sensitive mutant virus [5–7] ﬁrst isolated by
propagating MoMuLV in a thymus bone marrow cell line
(TB) taken from CFW/D mice. This virus has a defect in the
intracellular processing of the envelope precursor polypro-
tein (Pr80env) at the restrictive temperature [6–9]. Like
HIV, MoMuLV ts-1 infects CD4 cells, with subsequent CD4
depletion and a resulting immunodeﬁciency (see Table 1)
[10]. ts-1 is a murine gamma retrovirus that can induce T-
cell lymphomas in susceptible strains of mice after a long
incubation period [11].
As a simple retrovirus, ts-1 has only three genes (gag,
env, and pol). Infection with ts-1 results in an AIDS-like
syndrome in mice similar to HIV infection in humans
[10, 12–14]. The most important characteristic of ts1 to
our study is its eﬀects on MTCT by breastfeeding in mice
[2–4]. About 97% of uninfected neonatal mice that suckle
from an infected mother develop clinically symptomatic ts-
1 infection [3, 4]. Newborn BALB/c mice infected with
ts1 virus suﬀer from neurodegenerative disease resulting in
hind limb paralysis and immunologic disease characterized
by severe thymic atrophy associated with immunodeﬁciency
due to destruction of T-lymphocytes, and generalized body
wasting [7, 15]. Infectivity of ts-1 is signiﬁcantly related to its
temperature sensitivity [7], and can replicate optimally at a
permissive temperature of 34◦C[ 16]. This may explain why
the ts-1 virus can produce hind limb paralysis in newborn
mice and not in the adult, because the body temperature
of the newborn mice is lower (∼34◦C) than that of adult
(38.4◦C) [17]. The uniqueness of the ts-1 among other
murine retroviruses is that it can cause degenerative diseases
in mice similar to HIV in humans, by aﬀecting both the
central nervous system (CNS) and the immune system.
Infected T-lymphocytes have impaired function [14, 18].
The murine ts-1 model has been extensively used as a
small-animal model for retrovirus-induced neurodegenera-
tive disease [19]. Oxidative stress has been suggested as a
majormechanismforts1-inducedneurodegenerationandT-
celllossininfectednewbornmice[20].TheU3regionofts-1
controls the pathogenicity and targets cell type [21].
Transferofhumoralimmunitytots-1canbepassedfrom
mother to baby via breast milk and can provide protection
from neurodegenerative and immunologic disease in neona-
tal mice [22]. Chakraborty et al. [23], have further developed
thismurinemodeltostudytheperinataltransmissionofts-1.
Infected mothers can transmit the ts-1 virus vertically to oﬀ-
spring. They further demonstrated that mother-to-oﬀspring
transmission via breast milk can occur at nearly a 100%
incidence [4], and can cause lymphoma when control pups
suckle from ts-1 infected mothers. The pattern of proviral ts-
1 integration sites observed in these lymphoma tissues corre-
lates with the upregulation of mRNA expression of candidate
genes that may contribute to lymphomagenesis [4].
2.2. Mother-to-Child Transmission of HIV by Breastfeeding.
MTCT of HIV can occur in utero, intrapartum, or through
breastfeeding. Current strategies aimed at decreasing MTCT
of HIV have focused mainly on in utero and intrapartum
transmission. Prophylaxis with highly active antiretroviral
therapy (HAART) during pregnancy and through delivery
has substantially reduced the rate of MTCT of HIV at birth
[24]. Avoidance of breastfeeding by HIV-infected mothers
is the norm in developed countries throughout the world
[25]. However, for socioeconomic and cultural reasons, such
avoidance is not an acceptable or viable alternative for
many HIV-infected women in Africa and other resource
poor areas worldwide [26]. In these areas, breastfeeding
is the best and only source of infant nutrition, and safe
alternatives do not exist because of inadequate supplies of
formula and the lack of clean water. Breastfeeding, therefore,
accounts for a substantial proportion of the overall MTCTAdvances in Virology 3
Table 2: Percentages of changes in spleen, lymph node, and thymus due to MTCT of ts-1 virus by breastfeeding in control and infected
pups.
Group Description Sample size (n) Splenomegaly Lymph node
hypertrophy
Thymic
hypertrophy
1 Control pup nursed by infected surrogate mother 93 95.7% 79.1% 95.7%
2 Infected pup nursed by infected surrogate mother 94 92.6% 56.5% 92.6%
3 Infected pup nursed by control surrogate mother 108 46.3% 25.9% 46.3%
5 Infected pup nursed by biological mother 88 89.8% 61.4% 89.8%
4 & 6 Control—no infection 154 1.9% 0.0% 5.8%
Pregnant BALB/c mice
Oﬀspring infected by injection Oﬀspring uninfected (control)
Infected females Infected males (discarded) Control females Control males
Infected surrogate mother Infected biological mother Control surrogate mother Control biological mother
Group 1: control pups Group 5: infected pups Group 3: infected pups Group 6: control pups
Group 2: infected pups Group 4: control pups
Figure 1: Experimental plan for ts-1 breast milk transmission studies.
rate in developing countries. Breastfeeding for 15 months
accounts for 38% of the overall MTCT rate [27], and
if continued for 24 months, it accounts for 44% [28].
Richardson et al. [29] reported that if an infant ingests one
liter of breast milk then the probability of having the HIV-
1 infection is similar to that of heterosexual transmission.
Breast milk transmission depends on high maternal viral
load and status of immunodeﬁciency with mastitis and
durationofbreastfeedingincreasingtherateofHIVinfection
[29]. Breastfeeding by HIV positive women can reverse
the beneﬁts made in reducing perinatal HIV transmission
through the use of HAART during pregnancy and/or labor.
For example, in the Petra study of MTCT of HIV [30], the
beneﬁts of perinatal HAART prophylaxis were lost in the
breastfeeding group. In order to prevent milk-borne HIV,
HAART must be given throughout the breastfeeding period,
which is rarely a feasible option in developing countries.
Studies in primates with HIV-2 [31], simian immun-
odeﬁciency virus (SIV) and SHIV (SIV expressing HIV
envelope) [32, 33] have shown that primate lentiviruses can
be transmitted orally. After milk is swallowed, gastric acid
may inactivate some virus, but the buﬀering capacity of milk
may allow the remaining virus to enter into the lumen of
the gut, where there is extensive lymphoid tissue as a target
for HIV. Mixed feeding (breastmilk and formula) carries
a signiﬁcantly increased risk of HIV transmission, because
formula foods increase gut permeability [34]. These data
suggest that the intestine could be a site of HIV entry in
breast milk transmission, in addition to the oropharyngeal
cavity. In areas without clean water, WHO recommends
exclusively breastfeeding to avoid fatal diarrhea and the
increased risk of HIV infection related to mixed feeding of
formula and breast milk [35].
Several methods have been studied to decrease MTCT of
HIVinareaswherebreastfeedingisanecessity.Theseinclude
wet nursing by an HIV-negative woman, heat-treating the
mother’s milk with Holder pasteurization (62.5◦ for 30min),
leaving milk at room temperature for 30 minutes to allow
milk lipase to inactivate HIV, adding microbicides to milk
and standing for 5–10 minutes, or getting milk from a
h u m a nm i l kb a n k[ 35, 36]. Due to high cost, obtrusiveness,
inaccessibility, and/or inconvenience, none of these options
are practical in developing countries where breastfeeding
remains the only viable option for infant feeding and thus
a major route of vertical HIV transmission. Therefore, a
prophylaxis is urgently needed. However, in order to develop
an eﬀective prophylaxis, the exact mechanism of breast milk
transmission of retrovirus must be clearly determined. In-
depth study of the pathophysiology of retroviral transmis-
sion via breast milk using an animal model such as our ts-
1 model will provide mechanistic insights that can translate
into eﬀective human therapies.
2.3.BreastMilkTransmissionofMoMuLVts-1inBALB/cMice.
In the study of viral transmission by breast milk, use of4 Advances in Virology
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Figure 2: Viral load comparisons of infected and control mothers. Body, spleen, lymph node, and thymus weight comparisons for mothers
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Table 4: Flow cytometric Analysis of CD4+, CD8+, and CD19 Cells.
Flow Cytometric analysis
CD4 (T-cell) CD8 (T-cell) CD19 (B-cell)
Blood
Control 15.4±10.6 4.4±2.9 2.6±1.2
Infected (no lymphoma) 5.1±4.2 1.0±0.7 0.5±0.6
Infected (with lymphoma) 3.2±2.4 1.5±1.2 1.7±1.3
Spleen
Control 13.1±4.7 4.9±2.0 22.6±7.1
Infected (no lymphoma) 12.5±0.8 4.6±0.3 10.1±2.4
Infected (with lymphoma) 2.8±0.6 1.8±1.2 2.2±1.2
Thymus
Control 15.6±5.6 16.6±8.5 0.9±0.2
Infected (no lymphoma) 25.3±33.3 1.2±0.1 2.0±1.4
Infected (with lymphoma) 8.6±9.2 8.9±13.5 0.4±0.5
Lymph Node
Control (NA) (NA) (NA)
Infected (no lymphoma) (NA) (NA) (NA)
Infected (with lymphoma) 11.3±8.2 4.3±3.6 8.6±7.0
(NA): Not Available.
Infected
mouse mouse
Liver
Liver
Spleen
Spleen
Thymus
Control
Figure 4: Organomegaly in infected versus control mice.
Liver
Mesenteric
lymphnodes
Spleen
Figure 5: Manifestations of MoMuLV-ts-1 retroviral infection on
diﬀerent organ system.
a small animal model with a well-characterized immune
system, such as the mouse, is ideal. As mentioned above,
infection with ts-1 results in an AIDS-like syndrome. When
neonatal BALB/c mice less than 10 days old are injected
intraperitoneally with ts-1, clinically apparent infection
Infected Control mouse mouse
Spleen
Thymus
Lymph node
Heart
Figure 6: Excised organs from infected versus control mouse.
develops within 10 weeks. This clinical syndrome in mice
is characterized by progressive bilateral hind limb paralysis,
severe body wasting, and immunodeﬁciency [15]. Milder
clinical illness can be induced by varying the dose of virus
injected and/or the time of viral inoculation up to 10 days of
age. CD4 cells are depleted by apoptosis, yielding AIDS-like
clinical manifestations [12–14].
Several unique characteristics of this virus determine the
experimental manner in which it is evaluated. The infectivity
of this virus is strain speciﬁc and dependent upon the age
of the mouse at the time of exposure, but the temperature
sensitive nature of the virus does not aﬀect its in vivo
infectivity [15, 37]. BALB/c mice are a susceptible strain,
with clinical diseases developing in 98% of mice by week 10
after intraperitoneal injection. Viral injection of mice after
ten days of age does not result in clinically detectable disease
but does result in antibody production [19, 38]. Perinatal
transmission of ts-1 occurs in utero, intrapartum,a n dv i a
breastfeeding [2, 3]. Breastfeeding is a highly eﬀective route
of MTCT in this model: 95% to 99% of uninfected neonatal8 Advances in Virology
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Figure 7:ExamplesoftheﬂowcytometricanalysisshowingfrequencyofCD4+andCD8+cellsfromcontrolandinfectedoﬀspring.Samples
were tagged with CD3 FITC, CD4 APC and CD3 FITC, CD8 PE. Upper left quadrant (UL) shows na¨ ıve lymphocytes. Upper right quadrant
(UR) shows CD3+/CD4+ or CD3+/CD8+ frequency for cells positive for both CD3 and CD4 or CD3 and CD8 markers. Lower left quadrant
(LL) shows CD3−/CD4− or CD3−/CD8− frequency for cells negative for both CD3/CD4 or CD3/CD8 markers. Lower right quadrant (LR)
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Table 5: Retrovirus genera and type of species aﬀected.
Classiﬁcation of retroviruses
Genus Species Examples
Alpharetrovirus Birds Avian leukosis viruses (AVL), Rous sarcoma virus (RSV)
Betaretrovirus Mice, primates, and sheep Mouse mammary tumor virus (MMTV), Mason-Pﬁzer monkey virus
(MPMV), and Jaagsiekte sheep retrovirus (JSRV)
Gammaretrovirus Mice, cats, primates, and birds Murine leukemia virus (MLV), feline leukemia viruses, gibbon ape leukemia
virus, reticuloendotheliosis virus, and xenotropic murine retrovirus (xMRV)
Deltaretrovirus Cattle and primates Bovine leukemia virus, human T-lymphotropic virus
Epsilonretrovirus Fish Walleye dermal sarcoma virus
Lentivirus Primates, sheep, cats, and horses
Human immunodeﬁciency virus (HIV), simian immunodeﬁciency virus
(SIV), Maedi/visna virus, feline immunodeﬁciency virus (FIV), and equine
infectious anemia virus
Spumavirus Primates, cats, and cattle Human foamy virus (HFV), simian foamy virus (SFV), feline foamy virus,
and bovine foamy virus
C-onc
V-onc V-onc LTR LTR
Figure 8: Acute transforming virus, capture of a c-onc and over-
expression of v-onc by provirus.
LTR
Enhancer promoter
Exon 1 Exon 2
Figure 9: Enhancer of promoter insertion either upstream or
downstream of growth controlling cellular genes.
mice, if suckled from an infected mother, develop clinically
symptomatic ts-1 infection [3, 4].
Our laboratory was the ﬁrst to clearly demonstrate that
breast milk transmission in oﬀspring of ts-1 infected BALB/c
mice causing AIDS like condition. We have established a
mouse model for MTCT for MoMuLV ts-1 for in utero,
intrapartum, and postpartum (breastfeeding) routes of
transmission [2–4, 23]. The following information provide
some murine model data for retroviral transmission via
breastfeeding. Pregnant BALB/c female mice delivered pups
which were divided into experimental and control groups.
Seventy two hours after birth, the pups were injected
intraperitoneally (ip) with 0.1mL of 4.0 × 106 ﬀu/mL ts-1
virus and control pups were injected with 0.1mL DMEM
medium [2–4] .T h e s em i c ew e r ea l l o w e dt om a t ew i t h
uninfected males and produce oﬀspring. Within 10–12h
after birth, oﬀspring suckled either from control or ts1-
infected surrogate or biological mothers (Figure 1). Tissue
collection, histology, electron microscopy, ﬂow cytometry,
DNA extraction, PCR, and sequencing of viral DNA were
performed. Four hundred twenty one mice were divided into
6 groups as described in our previous paper [3]. Pups from
the ts-1 control mothers suckled from the infected surrogate
mothers (Group 1), pups from the infected mothers suckled
from the infected surrogate mothers (Group 2), or from
infected biological mothers (Group 5). In Group 3, infected
pups suckled from the control mothers. Groups 4 and 6 were
controls. Group 4 control pups suckled from the control
surrogate mothers, and Group 6, control pups suckled from
their control biological mothers.
The rate of postpartum ts-1 transmission in this study
was almost 100%. This rate is much higher than the MTCT
of HIV in infants via breastfeeding (about 20%–30%),
which is advantageous in an experimental animal model.
Maternal viral load appear to correlate with development
of lymphoma (Table 3; Figures 2 and 3), but further studies
are needed to verify this. The ﬁgures and tables listed below
show some of the gross morphology and ﬂow cytometric
data. Signiﬁcant and consistent increases in weights and
change in gross morphology of spleen, lymph node, and
thymus (Tables 2 and 3; Figures 4, 5,a n d6) are readily
apparent. Our ﬂow cytometric data shows decreases in CD4
and CD8 (Figure 7) cell population in the advanced stages of
lymphoma development. In addition, decreasing numbers of
CD8 and B-cells have been shown (Table 4) in the presence
of clinically apparent immunodeﬁciency and wasting.
3. Part II.ts-1 andLymphomagenesis
3.1. Retrovirus Induced Cancer. The ﬁrst reports of retro-
viruses associated with cancer occurred in the early 20th
century when an avian erythroblastosis virus (AEV) was iso-
lated from spontaneous erythroleukemia in a chicken [39].
Shortly after that, Peyton Rous demonstrated that chicken
sarcomas were infectious and could induce tumors when
transmittedintohealthybirds[40].Thesenovelobservations
were followed by multiple reports of retroviruses isolated
from a broad range of mammals such as rodents, cats,
sheep, and cows in association with both malignancies and
immunodeﬁciencies. The ﬁrst human retrovirus, human T-
lymphotropic virus type 1 (HTLV-1), was isolated in 1980
[41] and has been shown to induce adult T-cell leukemia
(ATL) [42].10 Advances in Virology
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Figure 10:Thisﬁgureshowsthecentriole-centrosomedivisionduringcellcycle(a),presenceofbothcentrioleandcentrosomeintheanimal
cell (b), and absence of centriole in the ﬁrst cleavage division of a mammalian egg (c).
Normal division
(a)
Tripolar
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Figure 11: Normal and abnormal cell division due to abnormal centriole-centrosome division. As a result, giant cells with multiple nuclei
may be present in a malignant cell.
Retroviruses are classiﬁed into seven genera. Oncogenic
retroviruses (retroviruses that induce tumorigenesis) belong
to the following genera (Table 5)[ 43, 44].
Oncogenic retroviruses which induce tumors can be
dividedintotwoclasses:acuteandslowtransformingviruses.
Acute transforming retroviruses induce polyclonal tumors
within 2 to 3 weeks after infection of the host. These
retroviruses induce tumors through acquisition and overex-
pressionofcellularproto-oncogenesthathavecapturedvirus
(Figure 8)[ 45]. An example is v-Abl in the Abelson Murine
Leukemia Virus [46].
In contrast, slow transforming retroviruses induce
mono- or oligoclonal tumors with a longer latency of several
months. These types of retroviruses do not carry viral
oncogenesandcancausetumorsby activating cellularproto-
oncogenes close to the proviral DNA integration site on the
host genome (Figure 9).
Elements in the proviral genome that regulate the viral
transcript also act at common integration sites (cis) on
cellulargene transcripts. Depending on whether the provirus
integrates into the genes or in the vicinity of the genes,
these elements can enhance or disrupt normal transcription,
and thus induce oncogenic mutations. These classes of
retroviruses have been found to induce tumors in many
animals, including birds (ALV and REV), and mice (MLV);
[45].Inadditiontothesetwogeneraltransformationgroups,
a small number of retroviruses induce tumors by expression
of their own oncogenic proteins. For example, human T-
cell leukemia virus types 1 and 2 (HTLV-1 and HTLV-
2, resp.) induce adult T-cell immortalization and leukemia
in human by expression of viral Tax protein. Tax has no
cellular homologue, and it works in trans to disrupt cellular
checkpoints and destabilize genome integrity [47] leading
to transformations that directly cause human cancer [48].Advances in Virology 11
Table 6: Gene expression analysis of the spleen tissues were used to investigate the centriole-centrosome pathway for infected versus control
mice. tacc3 showed the highest upregulation with 30.13-fold increase, much more than our previous report [4]. tpx2 and p53 showed
signiﬁcant downregulation. During this investigation, aurka did not show signiﬁcant upregulation. This is due to the variation in this group
of six mice used in this study. However, a trend of upregulation of aurka is evident in 3 mice in column 2.
Gene expression
Mouse ID tacc3 aurka ndel1 tpx2 p53 rhamm
Control 1 (NA) (NA) 1.18 (NA) (NA) (NA)
Control 2 (NA) (NA) 0.17 (NA) 0.45 0.56
Control 3 2.32 0.8 0.42 0.91 0.66 0.75
Control 4 0.37 0.96 2.78 1.85 1.95 1.53
Control 5 0.85 0.96 0.57 1.19 0.93 1.17
Control 6 0.64 1.52 0.09 0.17 (NA) (NA)
Control 7 0.82 0.76 1.81 0.88 (NA) (NA)
SEM 0.34 0.14 0.37 0.27 0.33 0.22
Normalized avg.
fold Exp. 1.00 1.00 1.00 1.00 1.00 1.00
Lymphoma 1 11.25 1.25 0.14 0.15 0.26 1.63
Lymphoma 2 (NA) 0.44 0.12 0.2 0.13 0.67
Lymphoma 3 (NA) 0.4 0.25 0.11 0.15 1.63
Lymphoma 4 53.53 2.41 0.2 0.15 0.71 0.88
Lymphoma 5 53.16 1.87 0.24 0.15 0.6 0.9
Lymphoma 6 2.57 (NA) 0.09 0.15 0.07 0.85
Avg Fold Exp. 30.13 1.27 0.17 0.15 0.32 1.09
SEM 13.52 0.39 0.03 0.01 0.11 0.17
P ≤ 0.05 0.04 0.53 0.07 0.01 0.05 0.75
(NA): data not available.
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Figure 12: Graph of fold change in gene expression versus
normalized control.
In AIDS-related lymphoma, patient studies indicate that
oncogene activation by insertional mutagenesis of the HIV
might be another mechanism by which HIV-1 can induce
cancer [49, 50].
The release of the complete mouse genome sequence and
the availability of reliable methods for isolation of proviral
ﬂanks have introduced the retroviral insertion mutagenesis
screen in mice as a powerful procedure to identify genes
contributing to tumorigenesis. Many oncogenes identiﬁed
in these screens have given a valuable basis for better
understanding the development of human cancer [45]. The
MLV utilizes a slow transformation mechanism to induce
leukemia or lymphoma in mice and is one of the retroviruses
that provides an excellent model to identify and study the
oncogenes involved in retrovirus-induced tumorigenesis.
3.2. Centrosomal Involvement in Cell Cycle and Cancer.
Centriole-centrosome is the microtubular organization cen-
ter (MTOC) and plays a major role during mitosis for
chromosomal arrangement at the equatorial plane during
metaphase and pulling the chromatids in two opposite
spindle poles during anaphase. Spindles start to organize as
soon as centrioles divide and two centrosomes are formed.
The spindle microtubules act like railroad tracks on which
the chromatids travel towards the poles with the help
of several motor proteins including dynein and kinesin.
However, the centriole is not an essential structure for many
cells including ﬁrst cleavage division of mammalian eggs
[51]. Figure 10 describes the centrosome-centriole cycle in a
typical animal cell at mitosis and the ﬁrst cleavage division of
a mammalian egg without the centriole. The centrosome—
which is an accumulation of amorphous materials around
the centriole—is present in most mammalian cells. In these12 Advances in Virology
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Figure 13: Pathway of Genes associated with spindle formation.
cells, the centrosome is an essential component in the
development of spindle poles and progression to mitosis and
cytokinesis. There are three types of spindles: kinetochore,
interpolar, and astral. The kinetochore spindle extends from
poles to chromosomes. The interpolar spindles run from
pole to pole with no connection to the chromosomes, while
the astral spindles run between centrosomes to the cell
cortex. Thus, three types of spindles play diﬀerent roles.
There are numerous centrosomal proteins and new pro-
teins are being discovered every year. Although the centriole-
centrosome system is essential for cell cycle and normal
chromosomal segregation, little is known about the intricate
details of this structure, which is extremely important in
the understanding of cancer development and progression.
For example, many cancers show abnormal mitosis leading
to tetraploidy and aneuploidy. According to Wang et al.
[52], many carcinomas may have either or both structural
and numerical abnormalities; this occurs during early stage
of tumorigenesis. This is also correlated with chromosomal
instability and tumor progression. Numerical chromosomal
abnormalities can also occur due to bipolar and tripolar or
tetrapolar spindle formation (Figure 11).
Unequal segregation of chromosomes leads to multi-
ploidy and/or aneuploidy. Viral gene insertion into the
normal genome close to the centrosomal genes may lead to
abnormal mRNA expression resulting in abnormal protein
production and activity. For example, increases in Tacc3
and Aurora A kinase (Aurka) can produce tumor like cells
[53, 54].
3.3. Insertion of Viral Genome into the Mouse Genome
Causing Abnormal Centrosomal Protein Production Leading
to Lymphomagenesis. A large number of investigations have
been carried out to study the development of lymphoma
by MoMuLV, but so far, little data are available on the
natural transmission of this retrovirus by breast milk causing
lymphoma. Extensive studies are needed on breast milk
transmitted retroviruses, since evidence exists that viruses
such as HTLV-1 or Epstein-Barr virus (EBV) may be
oncogenic and also have epidemiologic patterns indicating
perinatal or early childhood transmission. The best studied
of these viruses is EBV. Studies have shown that EBV
and MLV gene insertion into the host genome alters geneAdvances in Virology 13
expression leading to carcinogenesis [55–59]. We have
used inverse PCR (I-PCR), DNA cloning, sequencing, and
quantitative reverse transcriptase-PCR (qRT-PCR) to study
the viral integration into mouse genome. Tissue samples
from spleen and lymph nodes were used for the genomic
studies [4]. Using the primary PCR product as template,
secondary PCR was performed. After the PCR bands were
obtained, cloning was done and colonies with viral inserts
were located and analyzed. The diﬀerential expression of
candidate genes was obtained by using quantitative real-
time PCR. Gene speciﬁc primers were designed using Primer
Express software. GAPDH was used as “housekeeping” gene
to conﬁrm ampliﬁcation factor for each PCR product melt-
curve analysis process. RNA expression levels were calculated
by using ddCt method. Gene expression were recorded by
mRNA expression and reported as “fold change”. Statistical
analyses were performed by using statistical package of
the social sciences (SPSS). 35 genes were selected for
mRNA expression based on preselected criteria. Table 6 and
Figure 12 show the change in mRNA expression of six
genes Tacc3 shows the highest upregulation with 30.13-fold
increase, much more than our previous report [4].
How are changes in gene expression associated with
lymphoma in this murine model? In our mouse model,
about 50% of pups develop lymphoma. This high incidence
of lymphoma may be due to the genomic integration of viral
DNA into the mouse genome causing changes in nearby
genes. While viral gene insertion appears to be random, in
pups that develop lymphoma, there is a predilection for viral
insertion near genes involved in spindle formation. One of
the mechanisms of lymphoma development, therefore, may
be the alteration in spindle assembly-disassembly pathway.
Up or down regulation of these genes may occur, breaking
the balance of protein production, and causing abnormality
in spindle formation, chromosomal segregation, and sub-
sequent lymphoma production. Although there are many
genes involved in the spindle assembly pathway, we have
studied 6 genes predominately associated with viral genomic
integration in mice with lymphoma including tacc3, aurka,
tpx2, rhamm, ndel1 and p53. Of these 6 genes, we have
observed the highest fold increase of tacc3 followed by aurka.
Figure 13 shows the proteins (gene product) associated with
spindle formation.
AlltumorsamplesshowedincreasesinmRNAexpression
of tacc3 gene compared to the control group. Out of
the 6 genes reported in this study, two were upregulated,
including tacc3 and aurka. As previously reported, tacc3
showed the highest mRNA expression levels with an average
of 9.16-fold increase [4]. tacc3 is associated with centrosome
and microtubule-associated proteins that are essential for
mitotic spindle formation [60] and have been associated
with dysfunction in a variety of tumors. Tacc3 was also
identiﬁed as a novel prognostic marker in nonsmall cell
lung cancer [61]. Dysregulation of Tacc3 proteins have also
been related to ovarian cancer [62]. Schnieder et al. [63]
demonstrated the important role of Tacc3 in spindle assem-
bly and cellular survival, thus introducing it as a potential
therapeutic target in cancer cells. Deﬁciency of Tacc3 leads
to p53-mediated apoptosis [64]. Therefore, overexpression
of tacc3, as observed in our mouse model may cause the
downregulation of p53, causing inhibition of apoptosis, thus
leading to lymphoma.
Aurka connects microtubules to kinetochore and phos-
phorylates Tacc3, leading to its localization to spindle micro-
tubules during metaphase and promoting its growth from
centrosomes. Aurka is essential for accurate chromosome
segregation.OverexpressionofAurka leadstospindledefects,
aneuploidy, and tumor formation. Tpx2 and Rhamm helps
with stable bipolar spindle formation through its association
with Aurka [65–67]. Decrease in expression of these proteins
may cause spindle fragmentation, while increased expression
may cause disorganized, multipolar spindles coupled with
inability to appropriately align and segregate chromatids.
Ndel1 has a high aﬃnity for Tacc3, and its disruption
decreases centrosome targeting of Tacc3 [68]. p53 is a cell-
cycle checkpoint protein. DNA damage generally results
in phosphorylation of p53 leading to its dissociation from
MDM2 and acts as a transcription factor, arresting the cells
in the G1 phase of the cell cycle. Mutated or downregulated
p53 results in continued proliferation in damaged cells
and subsequent development of cancer. Upregulation of
aurka and tacc3 and downregulation of p53 are consistent
with abnormal cell division, aneuploidy, and tumorigenesis.
Downregulation of tpx2 is associated with abnormal spindle
formation with the presence of giant cells and the absence
of mitotic ﬁgures in histological specimens of lymphoma
tissue. However, spindle pathway disruption is not the only
mechanism by which malignancies develop or progress, but
it may be an important factor for breast milk-transmitted
retrovirus-induced cancer in the ts-1 mouse model.
4. Conclusion
A well-developed animal model can be extremely important
in the study of viral-induced cancer and immunodeﬁciency.
Although there are obvious diﬀerences between murine
and human cells, an appropriate mouse model can provide
important clues to the possible pathways of molecular
mechanisms of retroviral transmission and cancer devel-
opment and progression. While this paper reviews ts-1
as a small animal model of perinatal HIV transmission
and ts-1 in lymphomagenesis, it also raises a number of
questions that need further study. We believe that this
is a unique murine model for the study of retrovirus-
induced lymphomagenesis for multiple reasons. Mice have
been used extensively for genetic, physiological, biochemical,
immunological, endocrinological, and reproductive research
and an enormous body of background data—including the
entire murine genome—is already available. In our unique
murine model, breast milk transmission is near 100%, but
lymphoma development occurs in only 50% of infected pups
across all litters; therefore, an ideal internal control exists in
which to study causative genetic factors. Study of this model
may contribute to the understanding of molecular mecha-
nisms of spindle formation, chromosomal segregation, and
interactions between many centrosomal proteins and may
help clarify some of the cellular abnormalities leading to14 Advances in Virology
cancer. Some of these proteins and their inhibitors can be
used for diagnostic and/or therapeutic development.
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